These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 4579978)

  • 21. Dapsone-resistant Mycobacterium leprae in a patient receiving dapsone in low doses.
    Browne SG
    Int J Lepr Other Mycobact Dis; 1969; 37(3):296-301. PubMed ID: 4906048
    [No Abstract]   [Full Text] [Related]  

  • 22. Recent advances in the study of the leprosy bacillus.
    Rees RJ
    Sci Basis Med Annu Rev; 1969; ():320-35. PubMed ID: 4917843
    [No Abstract]   [Full Text] [Related]  

  • 23. Studies on sulphone resistant strains of M. leprae in field and institutionalized cases of leprosy.
    Balakrishnan S; Seshadri PS; Neelan PN; Venkataramaniah HN; Harikrishnan S; Bhatia VN
    Lepr India; 1983 Jan; 55(1):71-5. PubMed ID: 6348413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dapsone resistance in leprosy.
    Browne SG
    Trans St Johns Hosp Dermatol Soc; 1973; 59(2):225-9. PubMed ID: 4602407
    [No Abstract]   [Full Text] [Related]  

  • 25. Active surveillance of leprosy contacts in country with low prevalence rate.
    Kai M; Maeda Y; Maeda S; Fukutomi Y; Kobayashi K; Kashiwabara Y; Makino M; Abbasi MA; Khan MZ; Shah PA
    Int J Lepr Other Mycobact Dis; 2004 Mar; 72(1):50-3. PubMed ID: 15217314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical diagnosis of dapsone resistant leprosy.
    Taylor PM
    Lepr India; 1982 Jan; 54(1):117-22. PubMed ID: 7047897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absence of enhancing effect of trimethoprim on the activity of a sulfonamide against Mycobacterium leprae.
    Pattyn SR; Verdoolaege-Van Loo G
    Int J Lepr Other Mycobact Dis; 1972; 40(3):320. PubMed ID: 4574275
    [No Abstract]   [Full Text] [Related]  

  • 28. Further experience with the kinetic method for the study of drugs against Mycobacterium leprae in mice. Activities of DDS, DFD, ethionamide, capreomycin and PAM 1392.
    Shepard CC
    Int J Lepr Other Mycobact Dis; 1969; 37(4):389-97. PubMed ID: 4918202
    [No Abstract]   [Full Text] [Related]  

  • 29. Dihydropteroate synthase mutations in the folP1 gene predict dapsone resistance in relapsed cases of leprosy.
    Cambau E; Carthagena L; Chauffour A; Ji B; Jarlier V
    Clin Infect Dis; 2006 Jan; 42(2):238-41. PubMed ID: 16355335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does dapsone resistance really matter in the MDT era?
    Ji B
    Int J Lepr Other Mycobact Dis; 2001 Mar; 69(1):54-5. PubMed ID: 11480322
    [No Abstract]   [Full Text] [Related]  

  • 31. In vitro activity of a new rifamycin derivative against Mycobacterium leprae.
    Dhople AM; Dimova V
    Arzneimittelforschung; 1996 Feb; 46(2):210-2. PubMed ID: 8720317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Resistance of Mycobacterium leprae to sulfones (DDS) and rifampicin in recurring lepromatous leprosy in Martinique and Guadeloupe since February 1980].
    Guelpa-Lauras CC; Constant-Desportes M; Millan J; Grosset J
    Acta Leprol; 1982; (86-87):77-80. PubMed ID: 6816000
    [No Abstract]   [Full Text] [Related]  

  • 33. Dapsone resistance in Mycobacterium leprae.
    Gillis TP; Williams DL
    Lepr Rev; 2000 Dec; 71 Suppl():S91-5. PubMed ID: 11201896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacterial growth kinetics of "M. lufu" in the presence and absence of various drugs alone and in combination. A model for the development of combined chemotherapy against M. leprae?
    Seydel JK; Wempe EG
    Int J Lepr Other Mycobact Dis; 1982 Mar; 50(1):20-30. PubMed ID: 7042611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Comparative characterization of the antigenic composition of M. leprae and M. lufu].
    Salamatina OS; Diachina MN; Iushchenko AA; Chernousova LN; Kalinina ON; Parshin MP
    Probl Tuberk; 2001; (8):49-51. PubMed ID: 11767394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the activity of streptomycin on Mycobacterium leprae in mice.
    Pattyn SR; Saerens E
    Lepr Rev; 1978 Dec; 49(4):275-81. PubMed ID: 368476
    [No Abstract]   [Full Text] [Related]  

  • 37. The problem of dapsone-resistant leprosy.
    Pearson JM
    Int J Lepr Other Mycobact Dis; 1981 Dec; 49(4):417-20. PubMed ID: 7042605
    [No Abstract]   [Full Text] [Related]  

  • 38. Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
    Yamasaki PR; do Nascimento DC; Chelucci RC; de Faria Fernandes Belone A; Rosa PS; Diório SM; de Melo TR; Barbieri KP; Placeres MC; Carlos IZ; Chung MC; dos Santos JL
    Bioorg Med Chem Lett; 2014 Jul; 24(14):3084-7. PubMed ID: 24907144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adenosine triphosphate content of Mycobacterium leprae from leprosy patients.
    Dhople AM
    Int J Lepr Other Mycobact Dis; 1984 Jun; 52(2):183-8. PubMed ID: 6373626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro synergistic activity between ofloxacin and ansamycins against Mycobacterium leprae.
    Dhople AM; Ibanez MA; Gardner GD
    Arzneimittelforschung; 1993 Mar; 43(3):384-6. PubMed ID: 8387790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.